Overseas network, November 18 (Xinhua) according to NBC, Sky News and other media on the 18th, Pfizer announced that the vaccine jointly developed by Pfizer and German biotechnology company biontech reached 95% in the final data analysis of clinical trials, which has met the requirements of applying for emergency use authorization, and will submit an application to regulatory authorities within a few days.
Pfizer has previously said its new crown vaccine can prevent 90% of infections and is expected to apply for emergency use authorization in late November. If the application is successful, it means that the vaccine may be available in the United States by the end of this year. (overseas website Zhao Jianxing)
Pfizer plans to apply for emergency use authorization